- $1.79bn
- $1.74bn
- $1.80m
Annual balance sheet for Inhibrx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 11.5 | 129 | 131 | 274 | 278 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.438 | 0.615 | 0.878 | 0.257 | 0.778 |
| Prepaid Expenses | |||||
| Total Current Assets | 15.6 | 132 | 139 | 280 | 295 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 10.7 | 11.3 | 9.49 | 7.22 | 9.37 |
| Other Long Term Assets | |||||
| Total Assets | 26.5 | 144 | 150 | 291 | 308 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 20.6 | 31.4 | 22.5 | 27.6 | 56.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 60.6 | 68.3 | 98.1 | 233 | 264 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -34.1 | 75.5 | 52.4 | 58.1 | 43.5 |
| Total Liabilities & Shareholders' Equity | 26.5 | 144 | 150 | 291 | 308 |
| Total Common Shares Outstanding |